p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex
Name:
Mol._Cell._Biol.-2017-Tao-.pdf
Size:
1.480Mb
Format:
PDF
Description:
FInal Published Version
Author
Tao, ShashaLiu, Pengfei
Luo, Gang
Rojo de la Vega, Montserrat
Chen, Heping
Wu, Tongde
Tillotson, Joseph
Chapman, Eli
Zhang, Donna D.
Affiliation
Univ Arizona, Coll Pharm, Dept Pharmacol & ToxicolIssue Date
2017-04-15Keywords
KEAP1NRF2
autophagy
cancer chemoresistance
oxidative stress
p97
proteasome
protein quality control
ubiquitylation
Metadata
Show full item recordPublisher
AMER SOC MICROBIOLOGYCitation
p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex 2017, 37 (8):e00660-16 Molecular and Cellular BiologyJournal
Molecular and Cellular BiologyRights
Copyright © 2017 American Society for Microbiology.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Activation of the stress-responsive transcription factor NRF2 is the major line of defense to combat oxidative or electrophilic insults. Under basal conditions, NRF2 is continuously ubiquitylated by the KEAP1-CUL3-RBX1 E3 ubiquitin ligase complex and is targeted to the proteasome for degradation ( the canonical mechanism). However, the path from the CUL3 complex to ultimate proteasomal degradation was previously unknown. p97 is a ubiquitin-targeted ATP-dependent segregase that extracts ubiquitylated client proteins from membranes, protein complexes, or chromatin and has an essential role in autophagy and the ubiquitin proteasome system ( UPS). In this study, we show that p97 negatively regulates NRF2 through the canonical pathway by extracting ubiquitylated NRF2 from the KEAP1-CUL3 E3 complex, with the aid of the heterodimeric cofactor UFD1/NPL4 and the UBA-UBX containing protein UBXN7, for efficient proteasomal degradation. Given the role of NRF2 in chemoresistance and the surging interest in p97 inhibitors to treat cancers, our results indicate that dual p97/NRF2 inhibitors may offer a more potent and long-term avenue of p97-targeted treatment.Note
6 month embargo; Published online 23 January 2017.ISSN
0270-73061098-5549
Version
Final published versionSponsors
[ES023758]; [CA154377]; [ES015010]; [ES006694]Additional Links
http://mcb.asm.org/lookup/doi/10.1128/MCB.00660-16ae974a485f413a2113503eed53cd6c53
10.1128/MCB.00660-16